N
Nicolas Simon
Researcher at Aix-Marseille University
Publications - 165
Citations - 3097
Nicolas Simon is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Population & Pharmacokinetics. The author has an hindex of 31, co-authored 158 publications receiving 2612 citations. Previous affiliations of Nicolas Simon include University of the Mediterranean.
Papers
More filters
Journal ArticleDOI
Intravenous abuse of methylphenidate.
Journal ArticleDOI
Moxifloxacin Penetration in Bronchial Secretions of Mechanically Ventilated Patients with Pneumonia
Marc Leone,Jacques Albanèse,Emmanuelle Sampol-Manos,Nicolas Simon,Bruno Lacarelle,Bernard Bruguerolle,Claude Martin +6 more
TL;DR: The pharmacokinetics of moxifloxacin was studied in 17 mechanically ventilated patients with pneumonia and allowed one to achieve efficient concentrations in bronchial secretions and plasma.
Journal ArticleDOI
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients
Nicolas Simon,Jonathan Finzi,Jonathan Finzi,Guillaume Cayla,Guillaume Cayla,Gilles Montalescot,Gilles Montalescot,Jean-Philippe Collet,Jean-Philippe Collet,Jean-Sébastien Hulot +9 more
TL;DR: Carriage of CYP2C19*2 allele and the use of omeprazole/esomeprazole were associated with the inter-individual variability in the active metabolite clearance, explaining that a small variation of exposure may have a clinical relevance.
Journal ArticleDOI
Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction.
Benjamin A Guillet,Nicolas Simon,Raj Purgus,Celine Botta,Sophie Morange,Yvon Berland,Pascale Pisano +6 more
TL;DR: None of the data presented here could justify measurement of free concentration for therapeutic drug monitoring, and the large inter- and intravariability of MPA raises questions about the value of the use of therapeutic monitoring and limited sampling strategies as currently practiced.
Journal ArticleDOI
Pharmacological treatment of schizophrenia with comorbid substance use disorder
TL;DR: Direct and indirect evidence tends to stand in favour of the use of second-generation antipsychotics (SGAs), and particularly those with lower metabolic, cardiovascular and extrapyramidal side effects, as well as those with a depot formulation.